Trials / Terminated
TerminatedNCT00193024
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.
Detailed description
Upon determination of eligibility, all patients will receive: Docetaxel + Epirubicin Both drugs will be repeated at 21-day intervals
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | Epirubicin |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2003-10-01
- Completion
- 2004-10-01
- First posted
- 2005-09-19
- Last updated
- 2011-05-03
Source: ClinicalTrials.gov record NCT00193024. Inclusion in this directory is not an endorsement.